Sanofi (SNY) Net Income towards Common Stockholders (QoQ) (2009 - 2026)

Sanofi (SNY) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Sanofi	-	-	9.49 Bn

Historic Data

Download Data

Date	Value
Mar 31, 2026	-78.94%
Dec 31, 2025	-9.48%
Sep 30, 2025	125.80%
Jun 30, 2025	127.97%
Mar 31, 2025	-66.30%
Dec 31, 2024	92.01%
Sep 30, 2024	157.82%
Jun 30, 2024	-3.05%
Mar 31, 2024	-78.68%
Jun 30, 2016	9.13%
Mar 31, 2016	227.50%
Dec 31, 2015	-79.78%
Sep 30, 2015	25.85%
Jun 30, 2015	24.49%
Mar 31, 2015	-30.94%
Dec 31, 2014	5.95%
Sep 30, 2014	48.18%
Jun 30, 2014	-28.24%
Mar 31, 2014	2.96%
Dec 31, 2013	-10.68%